Patterns of metastatic spread in early breast cancer

Breast

Volumn 22, Issue 4, 2013, Pages 449-454

  Klevesath, M B ^a   Pantel, K ^b   Agbaje, O ^c   Provenzano, E ^a   Wishart, G C ^f   Gough, P ^d   Pinder, S E ^e   Duffy, S ^c   Purushotham, A D ^e  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d Kings Lynn Hospital NHS Trust ^*  (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f ANGLIA RUSKIN UNIVERSITY   (United Kingdom)

Author keywords

Breast cancer; Metastasis; Patterns

Indexed keywords

BONE SIALOPROTEIN; CHEMOKINE RECEPTOR CXCR4; INTERCELLULAR ADHESION MOLECULE 1; OSTEOPONTIN; VASCULOTROPIN C;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; BONE MARROW METASTASIS; BREAST CANCER; CANCER GRADING; CANCER RECURRENCE; CANCER SURGERY; CONTROLLED STUDY; DEATH; EARLY CANCER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SENTINEL LYMPH NODE BIOPSY; TISSUE MICROARRAY; TUMOR INVASION; TUMOR VOLUME; WIDE EXCISION;

EID: 84879787472     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.04.017     Document Type: Article

References (30)

1. Carter C.L., Allen C., Henson D.E. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989, 63(1):181-187.
2. Adair F., Berg J., Joubert L., Robbins G.F. Long-term followup of breast cancer patients: the 30-year report. Cancer 1974, 33(4):1145-1150.
3. Quiet C.A., Ferguson D.J., Weichselbaum R.R., Hellman S. Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up. JClin Oncol 1995, 13(5):1144-1151.
4. Diel I.J., Kaufmann M., Costa S.D., Holle R., von Minckwitz G., Solomayer E.F., et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. JNatl Cancer Inst 1996, 88(22):1652-1658.
5. Braun S., Pantel K., Muller P., Janni W., Hepp F., Kentenich C.R., et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. NEngl J Med 2000, 342(8):525-533.
6. Solakoglu O., Maierhofer C., Lahr G., Breit E., Scheunemann P., Heumos I., et al. Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci U S A 2002, 99(4):2246-2251.
7. Cote R.J., Rosen P.P., Lesser M.L., Old L.J., Osborne M.P. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. JClin Oncol 1991, 9(10):1749-1756.
8. Mansi J.L., Gogas H., Bliss J.M., Gazet J.C., Berger U., Coombes R.C. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 1999, 354(9174):197-202.
9. Weinschenker P., Soares H.P., Clark O., Del Giglio A. Immunocytochemical detection of epithelial cells in the bone marrow of primary breast cancer patients: a meta-analysis. Breast Cancer Res Treat 2004, 87(3):215-224.
10. Braun S., Vogl F.D., Naume B., Janni W., Osborne M.P., Coombes R.C., et al. Apooled analysis of bone marrow micrometastasis in breast cancer. NEngl J Med 2005, 353(8):793-802.
11. Giuliano A.E., Hawes D., Ballman K.V., Whitworth P.W., Blumencranz P.W., Reintgen D.S., et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. Jama 2011, 306(4):385-393.
12. Wiedswang G., Borgen E., Karesen R., Kvalheim G., Nesland J.M., Qvist H., et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. JClin Oncol 2003, 21(18):3469-3478.
13. Woelfle U., Cloos J., Sauter G., Riethdorf L., Janicke F., van Diest P., et al. Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res 2003, 63(18):5679-5684.
14. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordon-Cardo C., et al. Amultigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3(6):537-549.
15. NHS Cancer Screening Programmes, The Royal College of Pathologists Pathology reporting of breast disease 2005, NHS Cancer Screening Programmes, Sheffield. 3rd ed.
16. Borgen E., Naume B., Nesland J.M., Kvalheim G., Beiske K., Fodstad O., et al. Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1999, 1(5):377-388.
17. Solomayer E.F., Diel I.J., Meyberg G.C., Gollan C., Bastert G. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 2000, 59(3):271-278.
18. Coleman R.E., Rubens R.D. The clinical course of bone metastases from breast cancer. Br J Cancer 1987, 55(1):61-66.
19. Zlotnik A., Burkhardt A.M., Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol 2011, 11(9):597-606.
20. Kato M., Kitayama J., Kazama S., Nagawa H. Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res 2003, 5(5):R144-R150.
21. Su Y.C., Wu M.T., Huang C.J., Hou M.F., Yang S.F., Chai C.Y. Expression of CXCR4 is associated with axillary lymph node status in patients with early breast cancer. Breast 2006, 15(4):533-539. Epub 2005 Oct 18.
22. Kang H., Watkins G., Douglas-Jones A., Mansel R.E., Jiang W.G. The elevated level of CXCR4 is correlated with nodal metastasis of human breast cancer. Breast 2005, 14(5):360-367.
23. Salvucci O., Bouchard A., Baccarelli A., Deschenes J., Sauter G., Simon R., et al. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat 2005, 1-9.
24. Hirbe A.C., Morgan E.A., Weilbaecher K.N. The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases?. Curr Pharm Des 2010, 16(11):1284-1290.
25. Cabioglu N., Sahin A., Doucet M., Yavuz E., Igci A., OY E., et al. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. Clin Exp Metastasis 2005, 22(1):39-46.
26. Bauerle T., Peterschmitt J., Hilbig H., Kiessling F., Armbruster F.P., Berger M.R. Treatment of bone metastasis induced by MDA-MB-231 breast cancer cells with an antibody against bone sialoprotein. Int J Oncol 2006, 28(3):573-583.
27. Zhang J.H., Wang J., Tang J., Barnett B., Dickson J., Hahsimoto N., et al. Bone sialoprotein promotes bone metastasis of a non-bone-seeking clone of human breast cancer cells. Anticancer Res 2004, 24(3a):1361-1368.
28. Weber G.F., Lett G.S., Haubein N.C. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 2010, 103(6):861-869.
29. Tuck A.B., O'Malley F.P., Singhal H., Harris J.F., Tonkin K.S., Kerkvliet N., et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 1998, 79(5):502-508.
30. Rudland P.S., Platt-Higgins A., El-Tanani M., De Silva Rudland S., Barraclough R., Winstanley J.H., et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002, 62(12):3417-3427.